- Home
- NVNO vs BYSI Comparison
NVNO vs BYSI Comparison
Compare NVNO & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- BYSI
- Stock Information
- Founded
- NVNO 1987
- BYSI 2010
- Country
- NVNO United States
- BYSI United States
- Employees
- NVNO N/A
- BYSI N/A
- Industry
- NVNO Medical/Dental Instruments
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- BYSI Health Care
- Exchange
- NVNO Nasdaq
- BYSI Nasdaq
- Market Cap
- NVNO 61.9M
- BYSI 72.1M
- IPO Year
- NVNO N/A
- BYSI 2017
- Fundamental
- Price
- NVNO $2.45
- BYSI $1.31
- Analyst Decision
- NVNO
- BYSI
- Analyst Count
- NVNO 0
- BYSI 0
- Target Price
- NVNO N/A
- BYSI N/A
- AVG Volume (30 Days)
- NVNO 94.7K
- BYSI 24.5K
- Earning Date
- NVNO 05-07-2025
- BYSI 01-01-0001
- Dividend Yield
- NVNO N/A
- BYSI N/A
- EPS Growth
- NVNO N/A
- BYSI N/A
- EPS
- NVNO N/A
- BYSI N/A
- Revenue
- NVNO N/A
- BYSI N/A
- Revenue This Year
- NVNO N/A
- BYSI N/A
- Revenue Next Year
- NVNO $409.09
- BYSI N/A
- P/E Ratio
- NVNO N/A
- BYSI N/A
- Revenue Growth
- NVNO N/A
- BYSI N/A
- 52 Week Low
- NVNO $2.03
- BYSI $0.98
- 52 Week High
- NVNO $6.48
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- NVNO 44.81
- BYSI 44.17
- Support Level
- NVNO $2.05
- BYSI $1.03
- Resistance Level
- NVNO $2.44
- BYSI $1.27
- Average True Range (ATR)
- NVNO 0.23
- BYSI 0.15
- MACD
- NVNO 0.02
- BYSI 0.00
- Stochastic Oscillator
- NVNO 53.42
- BYSI 48.53
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.